Pulmonary Cell News Volume 4.35 | Sep 10 2015

Differential Deposition of Fibronectin by Asthmatic Bronchial Epithelial Cells
Researchers investigated the regulation of fibronectin (Fn) production in asthmatic or non-asthmatic human bronchial epithelial cells (HBECs), and whether Fn modulated HBEC proliferation and inflammatory mediator secretion. [Am J Physiol Lung Cell Mol Physiol] Abstract

Transcriptomic Analysis of Human Primary Bronchial Epithelial Cells after Chloropicrin Treatment
Investigators exposed human primary bronchial epithelial cells to two concentrations of chloropicrin for 6 or 48 hours and used genomic microarray, flow cytometry and TEM-analysis to monitor cellular responses to the exposures. [Chem Res Toxicol] Abstract

Complementary Roles of KCa3.1 Channels and β1-Integrin during Alveolar Epithelial Repair
Wound-healing assays demonstrated that the repair rates were increased in primary rat alveolar cell monolayers grown on a fibronectin matrix compared to non-coated supports, whereas an anti-β1-integrin antibody reduced it. [Respir Res] Full Article

Transport Mechanism of Nicotine in Primary Cultured Alveolar Epithelial Cells
Scientists characterized the uptake of nicotine in rat primary cultured type II (TII) and transdifferentiated type I-like (TIL) epithelial cells. In both TIL and TII cells, [³H]nicotine uptake was time- and temperature-dependent, and showed saturation kinetics. [J Pharm Sci] Abstract

LUNG CANCER

Inhibition of ABCB1 Overcomes Cancer Stem Cell-Like Properties and Acquired Resistance to MET Inhibitor in Non-Small Cell Lung Cancer
Investigators analyzed the antitumor effects of two MET inhibitors, PHA-665752 and crizotinib, in 10 non-small cell lung cancer cell lines. EBC-1 cells with MET amplification were the only cells that were sensitive to both MET inhibitors. [Mol Cancer Ther] Abstract

STAT1 Modification Improves Therapeutic Effects of Interferons on Lung Cancer Cells
Researchers found that expression of signal transducer and activator of transcription 1 (STAT1) or a modified STAT1 that is hyper-responsive to interferon (IFN) enhanced the effect of IFN-γ and, IFN-β on inhibition of human lung cancer cell proliferation, migration and invasiveness. [J Transl Med] Full Article

An Indolylquinoline Derivative Promotes Apoptosis in Human Lung Cancer Cells by Impairing Mitochondrial Functions
Scientists report that a synthetic indolylquinoline derivative, 3-((7-ethyl-1H-indol-3-yl)-methyl)-2-methylquinoline, inhibited the growth of human non-small cell lung cancer cells in dose- and time-dependent manners. [Apoptosis] Abstract

Chaetocin Induces Endoplasmic Reticulum Stress Response and Leads to Death Receptor 5-Dependent Apoptosis in Human Non-Small Cell Lung Cancer Cells
Researchers demonstrated that chaetocin effectively suppressed the growth of multiple lung cancer cells through inducing apoptosis in a death receptor 5-dependent manner. [Apoptosis] Abstract

Curcumin Inhibits Cell Proliferation and Induces Apoptosis of Human Non-Small Cell Lung Cancer Cells through the Upregulation of miR-192-5p and Suppression of PI3K/Akt Signaling Pathway
Treatment with curcumin inhibited cell proliferation, induced cell apoptosis and increased the caspase-3 activity of A549 cells. MicroRNA (miR)-192-5p mimics suppressed cell proliferation and increased cell apoptosis of A549 cells. [Oncol Rep] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

Synta Announces Presentations
Synta Pharmaceuticals Corp. announced that presentations related to ganetespib, a novel, potent small molecule inhibitor of heat shock protein 90 (Hsp90) in Phase III development, and STA-12-8666, the company’s leading candidate from its proprietary Hsp90 inhibitor drug conjugate program, was presented. [Press release from Synta Pharmaceuticals Corp. discussing research presented at the 16^th World Conference on Lung Cancer (WCLC), Denver] Press Release

OSE PHARMA Unveils Clinical and Immunological Outcomes in Patients with Brain Metastases Treated with Tedopi^® in a Phase II Trial
OSE Pharma SA unveiled encouraging results of survival and T-specific immune response in the patients with brain metastases treated with the company’s T-specific immunotherapy. [Press release from OSE Pharma SA discussing research presented at the 16^th World Conference on Lung Cancer (WCLC), Denver] Press Release

Transgene Announces Final Overall Survival Data from Phase IIb TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer
Transgene SA announced the presentation by Dr. Elisabeth Quoix of final data from the Phase IIb part of the TIME trial with TG4010 MUC1 targeted immunotherapy in non-small cell lung cancer. [Press release from Transgene SA discussing research presented at the 16^th World Conference on Lung Cancer (WCLC), Denver] Press Release

New Cohorts from CheckMate -012 Assess Optimal Dosing of Opdivo+Yervoy in the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Bristol-Myers Squibb Company announced updated results from the Opdivo (nivolumab)+Yervoy (ipilimumab) arms in CheckMate -012, a multi-arm Phase Ib trial evaluating Opdivo in patients with chemotherapy-naïve advanced non-small cell lung cancer. [Press release from Bristol-Myers Squibb Company discussing research presented at the 16^th World Conference on Lung Cancer (WCLC), Denver] Press Release

MGCD265 Demonstrates Clinical Efficacy with Confirmed Responses in NSCLC Patients with MET and Axl Gene Amplification
Mirati Therapeutics, Inc. presented data on the first non-small cell lung cancer (NSCLC) patient with AXL gene amplification enrolled in the MGCD265 Phase Ib expansion cohort. [Press release from Mirati Therapeutics, Inc. discussing research presented at the 16^th World Conference on Lung Cancer (WCLC), Denver] Press Release

Clovis Oncology Announces Data Presentations
Clovis Oncology announced that rociletinib, the company’s oral targeted covalent (irreversible) mutant-selective inhibitor of epidermal growth factor receptor (EGFR) in development for the treatment of EGFR-mutated, T790M positive non-small cell lung cancer, is the subject of four mini-oral presentations and two poster sessions. [Press release from Clovis Oncology Inc. discussing research presented at the 16^th World Conference on Lung Cancer (WCLC), Denver] Press Release

AstraZeneca to Update on Leading Lung Cancer Portfolio
Data was reported from across AstraZeneca’s lung cancer portfolio. Presentations featured 25 abstracts (including nine oral and four late breaker presentations) on the company’s lung cancer pipeline, designed to address the unmet needs of patients with different forms of lung cancer. [Press release from AstraZeneca discussing research presented at the 16^th World Conference on Lung Cancer (WCLC), Denver] Press Release

Verastem Presents Clinical and Preclinical Data
Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced oral and poster presentations. [Press release from Verastem, Inc. discussing research presented at the 16^th World Conference on Lung Cancer (WCLC), Denver] Press Release

From our sponsor:
Learn about mucociliary differentiation of primary bronchial epithelial cells. Watch the video.

Chugai’s ALK Inhibitor “Alectinib,” New Drug Application Submitted for ALK Positive Advanced Non-Small Cell Lung Cancer in the United States
Chugai Pharmaceutical Co., Ltd. and F. Hoffmann-La Roche Ltd. announced that Genentech, Inc. has filed a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) and the FDA has accepted the NDA, for ALK (anaplastic lymphoma kinase) inhibitor “alectinib hydrochloride” for the treatment of patient with ALK positive advanced non-small cell lung cancer who have progressed on or are intolerant to crizotinib. [Chugai Pharmaceutical Co., Ltd.] Press Release

Mayo Clinic and Hootsuite Introduce Social Media Training Program for Health Care
Hootsuite and Mayo Clinic Center for Social Media announced an industry-leading social media credential for medical and health care professionals. [Hootsuite Media Inc.] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the pulmonary cell community.

NEW Postdoctoral Researcher – Epigenetic Modifiers (Van Andel Research Institute)

Scientist – Pluripotent Stem Cell Biology Endoderm Lineages (STEMCELL Technologies Inc.)

Postdoctoral Research Fellow – Small Cell Lung Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Lung Cancer (Van Andel Research Institute)

Postdoctoral Fellow – Pulmonary Biology (The University of Alabama)

Postdoctoral Research Fellow – Cancer and Molecular Imaging (University of Michigan)

Postdoctoral Fellow – HMGA Chromatin Remodeling Proteins in Cancer and Stem Cell Biology (Johns Hopkins University School of Medicine)

Senior Research Technician (Qu Biologics Inc.)

Postdoctoral Research Associate – Airway Diseases (GlaxoSmithKline)

Harry Eagle Scholar Awards for Postdoctoral Candidates (Albert Einstein College of Medicine of Yeshiva University)

Postdoctoral Positions – Cancer Research (Rutgers University)

Postdoctoral Fellow – Pulmonary Fibrosis (University of Colorado School of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.